ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have received a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $107.3333.

A number of brokerages recently issued reports on ANIP. Barclays began coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price objective on the stock. Guggenheim increased their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $74.67 on Friday. The firm has a market cap of $1.68 billion, a PE ratio of 22.22 and a beta of 0.52. The stock’s fifty day moving average price is $78.66 and its two-hundred day moving average price is $84.64. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19. ANI Pharmaceuticals has a 1 year low of $56.71 and a 1 year high of $99.50.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, SVP Thomas Andrew Rowland sold 4,772 shares of the firm’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total value of $357,470.52. Following the completion of the transaction, the senior vice president directly owned 38,730 shares of the company’s stock, valued at $2,901,264.30. This trade represents a 10.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Ori Gutwerg sold 2,060 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $76.50, for a total value of $157,590.00. Following the completion of the transaction, the senior vice president owned 84,782 shares of the company’s stock, valued at approximately $6,485,823. This trade represents a 2.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 27,860 shares of company stock worth $2,114,771. Company insiders own 11.10% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ANIP. Hantz Financial Services Inc. grew its holdings in ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after buying an additional 237 shares in the last quarter. Advisors Asset Management Inc. bought a new position in shares of ANI Pharmaceuticals in the first quarter valued at approximately $28,000. Newbridge Financial Services Group Inc. boosted its position in shares of ANI Pharmaceuticals by 200.0% in the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after acquiring an additional 400 shares during the period. Kemnay Advisory Services Inc. purchased a new position in ANI Pharmaceuticals during the fourth quarter valued at approximately $48,000. Finally, State of Wyoming purchased a new position in ANI Pharmaceuticals during the second quarter valued at approximately $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.